• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Core One Labs Inc (OP: CLABF )

0.0645 -0.0232 (-26.45%)
Streaming Delayed Price Updated: 2:37 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Core One Labs Inc

Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
December 08, 2023
Via ACCESSWIRE
Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
December 01, 2023
Via ACCESSWIRE
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
August 04, 2023
Via ACCESSWIRE
Core One Labs' Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT
September 02, 2022
Via ACCESSWIRE
Core One Labs' Akome Achieves Significant Research Milestone with Positive Neurogenesis Stimulation Studies Results
August 18, 2022
Via ACCESSWIRE
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
August 01, 2023
Via ACCESSWIRE
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
July 28, 2023
Via ACCESSWIRE
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
July 11, 2023
Via ACCESSWIRE
Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
July 07, 2023
Via ACCESSWIRE
Core One in Talks with Multiple Companies to Supply Psilocybin
May 05, 2023
Via ACCESSWIRE
Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy
May 01, 2023
Via ACCESSWIRE
Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility
April 21, 2023
Via ACCESSWIRE
Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases
January 24, 2023
Via ACCESSWIRE
Core One Labs' Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers
January 13, 2023
Via ACCESSWIRE
Core One Labs’ Prepares for Commercial Production of API-Grade Psilocybin; Plans Initial Production Run at GMP Facility in January
November 18, 2022
Via ACCESSWIRE
Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities
October 21, 2022
Via ACCESSWIRE
European University to Fund Core One Labs' Akome Advanced Neurogenesis Stimulation Studies
October 14, 2022
Via ACCESSWIRE
Core One Labs Nearing GMP Production as Canada’s Province of Alberta Announces Game Changing Legislation
October 07, 2022
Via ACCESSWIRE
Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
September 30, 2022
Via ACCESSWIRE
Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds
September 23, 2022
Via ACCESSWIRE
Core One Labs' Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
September 16, 2022
Via ACCESSWIRE
Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin
September 01, 2022
Via ACCESSWIRE
Core One Labs Engages in Talks With GMP Manufacturing Partner for Commercial Scale Production of Proprietary Biosynthetic Psilocybin
August 26, 2022
Via ACCESSWIRE
Core One Labs' Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies
August 19, 2022
Via ACCESSWIRE
Core One Labs’ Vocan Successfully Converts Psilocin Precursor into Psilocybin
August 16, 2022
Via ACCESSWIRE
Core One Labs' Subsidiaries Successfully Produce Psilocin Precursor for Production to Psilocybin
August 12, 2022
Via ACCESSWIRE
Core One Labs Provides Clarification on Trading Activity
May 21, 2021
VANCOUVER, BC / ACCESSWIRE / May 21, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62, WKN:A2P8K3) (the "Company" or "Core One"). This news release is issued at the request of the... 
From Core One Labs Inc.
Via AccessWire
Topics Intellectual Property Law Enforcement
Exposures Intellectual Property Legal
Core One Labs Unaware of Any Material Change that Would Account for Significant Share Price Depreciation
May 04, 2021
VANCOUVER, BC / ACCESSWIRE / May 4, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company" or "Core One") wishes to confirm that management is unaware of any... 
From Core One Labs Inc.
Via AccessWire
Topics Intellectual Property Law Enforcement
Exposures Intellectual Property Legal
Core One Labs Appoints Patent Expert, Dr. Dan Polonenko, To Advisory Board
April 29, 2021
VANCOUVER, BC / ACCESSWIRE / April 29, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the "Company") is pleased to announce it has appointed Dr. Dan Polonenko to its... 
From Core One Labs Inc.
Via AccessWire
Topics Intellectual Property Law Enforcement
Exposures Intellectual Property Legal
Core One Labs Negotiates Milestone Acquisition With Akome Biotech Ltd.
April 17, 2021
VANCOUVER, BC / ACCESSWIRE / April 17, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the "Company") a biotechnology research and development life sciences enterprise... 
From Core One Labs Inc.
Via AccessWire
Topics Intellectual Property Law Enforcement
Exposures Intellectual Property Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap